AIDS and Behavior

, Volume 20, Issue 5, pp 1097–1107 | Cite as

Feasibility of Real Time Medication Monitoring Among HIV Infected and TB Patients in a Resource-Limited Setting

  • I. Marion de Sumari-de BoerEmail author
  • Jossy van den Boogaard
  • Kennedy M. Ngowi
  • Hadija H. Semvua
  • Krisanta W. Kiwango
  • Rob E. Aarnoutse
  • Pythia T. Nieuwkerk
  • Gibson S. Kibiki
Original Paper


HIV infected and tuberculosis (TB) patients need high levels of treatment adherence to achieve optimal treatment outcomes. We conducted a pilot-study on real time medication monitoring (RTMM) in a resource-limited setting. We enrolled five HIV infected and five TB patients from Kilimanjaro, Tanzania. They took their medication using RTMM. When the device was not opened on time, patients received a reminder SMS. After 3 months, we interviewed patients. Six patients (60 %) reached adherence of >95 %. Nine-hundred-twenty-two of 1104 intakes (84 %) were on time. Five-hundred reminders (45 %) were sent, of which 202 (40 %) were incorrect, because of an unstable mobile network. Nine patients found the device helpful and nine mentioned it keeps medication safe. Six patients reported that the size was too big. Five patients mentioned they received incorrect reminders. The device is considered useful in Kilimanjaro. Optimization of the device should consider network connectivity and the size of the device.


HIV Tuberculosis Adherence Real time medication monitoring Resource-limited setting 



This study received financial support from the Aidsfonds (Amsterdam, the Netherlands) through Grant 20130003. We would like to thank the participants for taking part in this study. We would also like to thank Mrs. Malema from the TB clinic of Mawenzi Hospital Moshi and Mrs. Lyimo from IDC in KCMC, Moshi for including the participants in this study. In addition, we would like to thank Dr. Chelangwa from Mawenzi Hospital and Dr. Maro from KCMC for allowing us to collect data in their departments.


  1. 1.
    Amberbir A, Woldemichael K, Getachew S, Girma B, Deribe K. Predictors of adherence to antiretroviral therapy among HIV-infected persons: a prospective study in Southwest Ethiopia. BMC Public Health. 2008;8:265.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Amico KR, Harman JJ, Johnson BT. Efficacy of antiretroviral therapy adherence interventions: a research synthesis of trials, 1996 to 2004. J Acquir Immune Defic Syndr. 2006;41(3):285–97.CrossRefPubMedGoogle Scholar
  3. 3.
    Ammassari A, Trotta MP, Murri R, et al. Correlates and predictors of adherence to highly active antiretroviral therapy: overview of published literature. J Acquir Immune Defic Syndr. 2002;31(Suppl 3):S123–7.CrossRefPubMedGoogle Scholar
  4. 4.
    Ammassari A, Trotta MP, Shalev N, et al. Timed short messaging service improves adherence and virological outcomes in HIV-1-infected patients with suboptimal adherence to antiretroviral therapy. J Acquir Immune Defic Syndr. 2011;58(4):e113–5.CrossRefPubMedGoogle Scholar
  5. 5.
    Bangsberg DR. Less than 95% adherence to nonnucleoside reverse-transcriptase inhibitor therapy can lead to viral suppression. Clin Infect Dis. 2006;43(7):939–41.CrossRefPubMedGoogle Scholar
  6. 6.
    Bangsberg DR. Preventing HIV antiretroviral resistance through better monitoring of treatment adherence. J Infect Dis. 2008;197(Suppl 3):S272–8.CrossRefPubMedGoogle Scholar
  7. 7.
    Barclay E. Text messages could hasten tuberculosis drug compliance. Lancet. 2009;373(9657):15–6.CrossRefPubMedGoogle Scholar
  8. 8.
    Berg KM, Arnsten JH. Practical and conceptual challenges in measuring antiretroviral adherence. J Acquir Immune Defic Syndr. 2006;43(Suppl 1):S79–87.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Bova CA, Fennie KP, Knafl GJ, et al. Use of electronic monitoring devices to measure antiretroviral adherence: practical considerations. AIDS Behav. 2005;9(1):103–10.CrossRefPubMedGoogle Scholar
  10. 10.
    Coomes CM, Lewis MA, Uhrig JD, et al. Beyond reminders: a conceptual framework for using short message service to promote prevention and improve healthcare quality and clinical outcomes for people living with HIV. AIDS Care. 2011;24(3):348–57.CrossRefPubMedGoogle Scholar
  11. 11.
    da Costa TM, Barbosa BJ, Gomes e Costa DA, et al. Results of a randomized controlled trial to assess the effects of a mobile SMS-based intervention on treatment adherence in HIV/AIDS-infected Brazilian women and impressions and satisfaction with respect to incoming messages. Int J Med Inform. 2012;81:257–69.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    de Boer M. Hakuna shida! The influence of costs, care, community and counseling on adherence to ARV in Kilimanjaro. 2008.Google Scholar
  13. 13.
    de Boer M. Combination antiretroviral therapy among immigrant and indigenous HIV infected patients: quality of life and treatment adherence. Dissertation University of Amsterdam, Amsterdam. 2011.Google Scholar
  14. 14.
    de Boer IM, Prins JM, Sprangers MA, Nieuwkerk PT. Using different calculations of pharmacy refill adherence to predict virological failure among HIV-infected patients. J Acquir Immune Defic Syndr. 2010;55(5):635–40.CrossRefPubMedGoogle Scholar
  15. 15.
    de Bruin M, Viechtbauer W, Schaalma HP, et al. Standard care impact on effects of highly active antiretroviral therapy adherence interventions: a meta-analysis of randomized controlled trials. Arch Intern Med. 2010;170(3):240–50.CrossRefPubMedGoogle Scholar
  16. 16.
    de Bruin M, Hospers HJ, van Breukelen GJ, et al. Electronic monitoring-based counseling to enhance adherence among HIV-infected patients: a randomized controlled trial. Health Psychol. 2010;29(4):421–8.CrossRefPubMedGoogle Scholar
  17. 17.
    Evalan BV. Real time medication monitoring with optional smart reminding. Internet. 2014;2-2-2015.Google Scholar
  18. 18.
    Girard P, Sheiner LB, Kastrissios H, Blaschke TF. Do we need full compliance data for population pharmacokinetic analysis? J Pharmacokinet Biopharm. 1996;24(3):265–82.CrossRefPubMedGoogle Scholar
  19. 19.
    Green J, Thorogood N. Chapter 8: Analysing qualitative data. Qualitative methods for health research. London: Sage; 2004. p. 173.Google Scholar
  20. 20.
    Haberer JE, Kahane J, Kigozi I, et al. Real-time adherence monitoring for HIV antiretroviral therapy. AIDS Behav. 2010;14(6):1340–6.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Haberer JE, Kwanuka J, Nansera D, et al. Real-time adherence monitoring of antiretroviral therapy among HIV-infected adults and children in rural Uganda. AIDS. 2013;27:2166–8.CrossRefPubMedGoogle Scholar
  22. 22.
    Hettema JE, Hosseinbor S, Ingerskoll KS. Feasibility and reliability of interactive voice response assessment of HIV medication adherence: research and clinical implications. HIV Clin Trials. 2012;13(5):271–7.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    IAPAC. Feeling watched: emotional and moral effects of Wisepill use promote adherence for adults taking antiretroviral therapy (ART) in Rural Southwestern Uganda. Adherence 2015; A decade of success, a world of opportunities. 2015.Google Scholar
  24. 24.
    Kelly JD, Giordano TP. Mobile phone technologies improve adherence to antiretroviral treatment in a resource-limited setting: a randomized controlled trial of text message reminders. AIDS. 2011;25(8):1137–9.CrossRefPubMedGoogle Scholar
  25. 25.
    Lester RT, Mills EJ, Kariri A, et al. The HAART cell phone adherence trial (WelTel Kenya1): a randomized controlled trial protocol. Trials. 2009;10:87.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Lester R, Mills E, Kariri A, et al. Effects of a mobile phone short message service on antiretroviral treatment adherence in Kenya (WelTel Kenya1): a randomised trial. Lancet. 2010;376:1838–45.CrossRefPubMedGoogle Scholar
  27. 27.
    Lyimo RA, van den Boogaard J, Msoka E, et al. Measuring adherence to antiretroviral therapy in northern Tanzania: feasibility and acceptability of the Medication Event Monitoring System. BMC Public Health. 2011;11:92.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Lyimo RA, de Bruin M, van den Boogaard J, et al. Determinants of antiretroviral therapy adherence in northern Tanzania: a comprehensive picture from the patient perspective. BMC Public Health. 2012;12:716.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Mbuagbaw L, Thabane L, Ongolo-Zogo P, et al. The Cameroon mobile phone SMS (CAMPS) trial: a protocol for a randomized controlled trial of mobile phone text messaging versus usual care for improving adherence to highly active anti-retroviral therapy. Trials. 2011;12:5.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Ministry of Health and Social Welfare URoT. Manual of the National Tuberculosis and Leprosy Programme in Tanzania. 5th ed. Dar es Salaam: MoH; 2010.Google Scholar
  31. 31.
    Munro SA, Lewin SA, Smith HJ, et al. Patient adherence to tuberculosis treatment: a systematic review of qualitative research. PLoS Med. 2007;4(7):e238.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Nsanzimana S, Ruton H, Lowrance DW, et al. Cell phone-based and internet-based monitoring and evaluation of the national antiretroviral treatment program during rapid scale-up in Rwanda: TRACnet, 2004-2010. J Acquir Immune Defic Syndr. 2012;59(2):e17–23.CrossRefPubMedGoogle Scholar
  33. 33.
    Orrell C, Cohen K, Mauff K, et al. A randomised controlled trial of real-time electronic adherence monitoring with text message dosing reminders in people starting first-line antiretroviral therapy. J Acquir Immune Defic Syndr. 2015;70(3):e73–83.CrossRefGoogle Scholar
  34. 34.
    Ortego C, Huedo-Medina TB, Llorca J, et al. Adherence to highly active antiretroviral therapy (HAART): a meta-analysis. AIDS Behav. 2011;15:1381–96.CrossRefPubMedGoogle Scholar
  35. 35.
    Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000;133(1):21–30.CrossRefPubMedGoogle Scholar
  36. 36.
    Pop-Eleches C, Thirumurthy H, Habyarimana JP, et al. Mobile phone technologies improve adherence to antiretroviral treatment in a resource-limited setting: a randomized controlled trial of text message reminders. AIDS. 2011;25(6):825–34.CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Ramadhani HO, Thielman NM, Landman KZ, et al. Predictors of incomplete adherence, virologic failure, and antiviral drug resistance among HIV-infected adults receiving antiretroviral therapy in Tanzania. Clin Infect Dis. 2007;45(11):1492–8.CrossRefPubMedGoogle Scholar
  38. 38.
    Rubio A, Cox C, Weintraub M. Prediction of diltiazem plasma concentration curves from limited measurements using compliance data. Clin Pharmacokinet. 1992;22(3):238–46.CrossRefPubMedGoogle Scholar
  39. 39.
    Sabin LL, Bachman DeSilva M, Gill CJ, et al. Improving adherence to antiretroviral therapy with triggered real-time text message reminders: the China adherence through technology study. J Acquir Immune Defic Syndr. 2015;69(5):551–9.CrossRefPubMedGoogle Scholar
  40. 40.
    Shuter J, Sarlo JA, Kanmaz TJ, Rode R, Zingman BS. HIV-infected patients receiving lopinavir/ritonavir-based antiretroviral therapy achieve high rates of virologic suppression despite adherence rates less than 95%. J Acquir Immune Defic Syndr. 2007;45(1):4–8.CrossRefPubMedGoogle Scholar
  41. 41.
    Siedner MJ, Lankowski A, Musinga D, et al. Optimizing network connectivity for mobile health technologies in sub-Saharan Africa. PLoS One. 2012;7(9):e45643.CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Simoni JM, Pearson CR, Pantalone DW, Marks G, Crepaz N. Efficacy of interventions in improving highly active antiretroviral therapy adherence and HIV-1 RNA viral load. A meta-analytic review of randomized controlled trials. J Acquir Immune Defic Syndr. 2006;43(Suppl 1):S23–35.CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    van den Boogaard J. Non-adherence to tuberculosis treatment: an integral approach to measure and prevent it. Dissertation Radboud University, Nijmegen. 2011.Google Scholar
  44. 44.
    van den Boogaard J, Lyimo R, Irongo CF, et al. Community vs. facility-based directly observed treatment for tuberculosis in Tanzania’s Kilimanjaro Region. Int J Tuberc Lung Dis. 2009;13(12):1524–9.PubMedGoogle Scholar
  45. 45.
    van den Boogaard J, Boeree MJ, Kibiki GS, Aarnoutse RE. The complexity of the adherence-response relationship in tuberculosis treatment: why are we still in the dark and how can we get out? Trop Med Int Health. 2011;16(6):693–8.CrossRefPubMedGoogle Scholar
  46. 46.
    van den Boogaard J, Lyimo RA, Boeree MJ, Kibiki GS, Aarnoutse RE. Electronic monitoring of treatment adherence and validation of alternative adherence measures in tuberculosis patients: a pilot study. Bull World Health Organ. 2011;89(9):632–9.CrossRefPubMedPubMedCentralGoogle Scholar
  47. 47.
    van den Boogaard J, Msoka E, Homfray M, et al. An exploration of patient perceptions of adherence to tuberculosis treatment in Tanzania. Qual Health Res. 2012;22(6):835–45.CrossRefPubMedGoogle Scholar
  48. 48.
    Vervloet M, van Dijk L, Santen-Reestman J, et al. Improving medication adherence in diabetes type 2 patients through Real Time Medication Monitoring: a randomised controlled trial to evaluate the effect of monitoring patients’ medication use combined with short message service (SMS) reminders. BMC Health Serv Res. 2011;11:5.CrossRefPubMedPubMedCentralGoogle Scholar
  49. 49.
    Vervloet M, van Dijk L, de Bakker DH, et al. Short- and long-term effects of real-time medication monitoring with short message service (SMS) reminders for missed doses on the refill adherence of people with Type 2 diabetes: evidence from a randomized controlled trial. Diabet Med. 2014;31(7):821–8.CrossRefPubMedGoogle Scholar
  50. 50.
    Vervoort SC, Borleffs JC, Hoepelman AI, Grypdonck MH. Adherence in antiretroviral therapy: a review of qualitative studies. AIDS. 2007;21:271–81.CrossRefPubMedGoogle Scholar
  51. 51.
    Vrijens B, Goetghebeur E. The impact of compliance in pharmacokinetic studies. Stat Methods Med Res. 1999;8(3):247–62.CrossRefPubMedGoogle Scholar
  52. 52.
    Vrijens B, Tousset E, Rode R, et al. Successful projection of the time course of drug concentration in plasma during a 1-year period from electronically compiled dosing-time data used as input to individually parameterized pharmacokinetic models. J Clin Pharmacol. 2005;45(4):461–7.CrossRefPubMedGoogle Scholar
  53. 53.
    Wilson IB, Bangsberg DR, Shen J, et al. Multisite Adherence Collaboration on HIV 14 Investigators. Heterogeneity among studies in rates of decline of antiretroviral therapy adherence over time: results from the multisite adherence collaboration on HIV 14 study. J Acquir Immune Defic Syndr. 2013;64:448–54.CrossRefPubMedPubMedCentralGoogle Scholar
  54. 54.
    World Health Organization. Adherence to long-term therapies. Evidence for action. Geneva: WHO; 2003.Google Scholar

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  • I. Marion de Sumari-de Boer
    • 1
    Email author
  • Jossy van den Boogaard
    • 1
  • Kennedy M. Ngowi
    • 1
  • Hadija H. Semvua
    • 1
  • Krisanta W. Kiwango
    • 1
  • Rob E. Aarnoutse
    • 3
  • Pythia T. Nieuwkerk
    • 2
  • Gibson S. Kibiki
    • 1
  1. 1.Department of clinical trials, Kilimanjaro Clinical Research InstituteMoshiTanzania
  2. 2.Department of Medical PsychologyAmsterdam Medical Center, University of AmsterdamAmsterdamThe Netherlands
  3. 3.Department of PharmacyRadboud University Medical CenterNijmegenThe Netherlands

Personalised recommendations